BioCardia Files 8-K: Other Events & Financials

TL;DR

BioCardia dropped an 8-K on 8/29 - check it for company updates and financials.

AI Summary

BioCardia, Inc. filed an 8-K on August 29, 2024, reporting other events and financial statements. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and headquartered in Sunnyvale, California.

Why It Matters

This filing provides updates on significant company events and financial reporting, which are crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events or financial updates without immediate, drastic implications.

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• Tiger X Medical, Inc. (company) — Former company name
• August 29, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Sunnyvale, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
• $0.001 — 0 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"
• $3.00 — mon Warrants"), at an offering price of $3.00 per share of Common Stock and accompany
• $2.999 — f Common Stock, at an offering price of $2.999 per Pre-Funded Warrant and accompanying
• $6.3 million — mpany from the Registered Offering were $6.3 million after deducting the Placement Agent's (
• $3 — is exercisable at a price per share of $3.00, and each Pre-Funded Warrant is exer
• $0.3 million — h placement commission of approximately $0.3 million and reimbursed an aggregate of $60,000
• $60,000 — million and reimbursed an aggregate of $60,000 of the Placement Agent's expenses in co

Filing Documents

• bcda20240831_8k.htm (8-K) — 32KB
• ex_720357.htm (EX-1.1) — 61KB
• ex_720358.htm (EX-4.1) — 103KB
• ex_720359.htm (EX-4.2) — 111KB
• ex_720360.htm (EX-99.1) — 267KB
• 0001437749-24-028190.txt ( ) — 815KB
• bcda-20240829.xsd (EX-101.SCH) — 3KB
• bcda-20240829_def.xml (EX-101.DEF) — 11KB
• bcda-20240829_lab.xml (EX-101.LAB) — 15KB
• bcda-20240829_pre.xml (EX-101.PRE) — 11KB
• bcda20240831_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On August 29, 2024, BioCardia, Inc. (the "Company") entered into securities purchase agreements (the "Purchase Agreements") with certain purchasers, pursuant to which the Company agreed to issue, and sell and the purchasers, in the aggregate to buy, in a public offering (the "Registered Offering") (i) 1,377,990 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), and accompanying warrants to purchase up to 1,377,990 shares of Common Stock (the "Common Warrants"), at an offering price of $3.00 per share of Common Stock and accompanying Common Warrant, and (ii) pre-funded warrants (the "Pre-Funded Warrants" and together with the Common Warrants the "Warrants") to purchase up to 1,022,010 shares of Common Stock and accompanying Common Warrants to purchase up to 1,022,010 shares of Common Stock, at an offering price of $2.999 per Pre-Funded Warrant and accompanying Common Warrant, which represents the same price per share of Common Stock and accompanying Common Warrant less the $0.001 per share exercise price of the Pre-Funded Warrants. Certain of the Company's directors and executive officers purchased an aggregate of 211,000 shares of Common Stock and accompanying Common Warrants. In addition, in connection with closing, the Company will issue 988,333 shares of Common Stock upon the pre-closing exercise of Pre-Funded Warrants, which will result in the Company having Pre-Funded Warrants to purchase 33,677 shares of Common Stock outstanding immediately following the closing. The expected net proceeds to the Company from the Registered Offering were $6.3 million after deducting the Placement Agent's (as defined below) fees and other offering expenses. Each Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions. The Company expects to cl

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits The following exhibits are filed as part of this report: Exhibit No. Description 1.1# Placement Agency Agreement dated August 29, 2024, between BioCardia, Inc. and A.G.P./Alliance Global Partners. 4.1 Form of Pre-Funded Warrant 4.2 Form of Common Warrant 99.1# Form of Securities Purchase Agreement dated August 29, 2024, by and among BioCardia, Inc. and the purchasers identified on the signature pages thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) # Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: September 3, 2024

View Full Filing

View this 8-K filing on SEC EDGAR